Orion Oyj (ORINY)

Market Cap	6.48B
Revenue (ttm)	1.59B
Net Income (ttm)	369.95M
Shares Out	n/a
EPS (ttm)	2.63
PE Ratio	17.52
Forward PE	n/a
Dividend	0.48 (2.12%)
Ex-Dividend Date	Oct 16, 2024

Volume	n/a
Open	22.76
Previous Close	22.76
Day's Range	22.76 - 22.76
52-Week Range	17.50 - 28.55
Beta	0.36
Analysts	n/a
Price Target	n/a
Earnings Date	Feb 25, 2025

About Orion Oyj

Orion Oyj develops, manufactures, and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients (APIs) in Finland, Scandinavia, rest of Europe, North America, and internationally. The company provides prescription drugs and self-care products, which includes Nubeqa for the treatment of prostate cancer; Precedex, Dexdor, and Precedex for human use; Burana for inflammatory pain; Divina series for menopausal symptoms; Trexan for rheumatoid arthritis and cancer; Stalevo, Entacapone, and Comtess/Comtan for Parkinson’s diseas...

• Industry: Drug Manufacturers - General
• Sector: Healthcare
• Founded: 1917
• Employees: 3,632
• Stock Exchange: OTCMKTS
• Ticker Symbol: ORINY

Financial Performance

In 2023, Orion Oyj's revenue was 1.19 billion, a decrease of -11.26% compared to the previous year's 1.34 billion. Earnings were 216.80 million, a decrease of -37.97%.

Financial numbers in EUR